World

Trump details aspirin habit, denies falling asleep in meetings

Jan 03, 2026

Washington [US], January 3: US President Donald Trump said he has for years taken a daily dose of aspirin higher than medically recommended, citing habit and superstition, according to an interview with the Wall Street Journal.
Trump said the practice has made him more prone to bruising, injuries he has at times tried to conceal cosmetically and which have prompted questions about his health.
"I'm a little superstitious," the 79-year-old said.
"They say aspirin is good for thinning out the blood, and I don't want thick blood pouring through my heart," Trump told the newspaper.
"I want nice, thin blood pouring through my heart. Does that make sense?" In the interview, Trump also disclosed new details about medical imaging he underwent last October, saying he had a computed tomography (CT) scan rather than a magnetic resonance imaging (MRI) scan, as he had previously stated.
Trump, who said he is in "perfect" health, also dismissed accusations that he had fallen asleep during recent White House meetings. Videos appeared to show him struggling to stay alert. "Sometimes they'll take a picture of me blinking, blinking, and they'll catch me with the blink," Trump said.
The White House said after the interview that the president is fully fit to carry out his duties.
Source: Qatar Tribune

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026